Eltrombopag/Eltrombopag: an effective treatment option for patients with thrombocytopenia

Immune thrombocytopenia (ITP) is a disease caused by abnormalities in the autoimmune system, characterized by a reduced number of platelets and an increased tendency to bleed. Eltrombopag/Eltrombopag, as an innovative oral small molecule drug, has shown significant efficacy in the treatment of such patients.

Eltrombopag is a non-peptide thrombopoietin receptor agonist (TPO-RA), which can bind tightly to the thrombopoietin receptor, thereby stimulating the proliferation of megakaryocytes in the bone marrow, thereby increasing platelet production. This makes eltrombopag an effective treatment for a variety of thrombocytopenia-related conditions, including chronic immune thrombocytopenia, thrombocytopenia associated with chronic hepatitis C, and severe aplastic anemia that does not respond well to standard immunosuppressive therapy.

In controlled studies lasting 6 weeks to 6 months, eltrombopag successfully increased platelet counts to 50×10^9/L or higher in approximately 60% to 80% of patients, significantly reducing bleeding events. This data provides strong evidence for the effectiveness of eltrombopag in increasing platelet counts and reducing the risk of bleeding. Eltrombopag may also be associated with some adverse events (AEs) during treatment. The most common adverse events include headache and nasopharyngitis, which are usually mild to moderate and can be controlled with appropriate medical management.

Due to its unique mechanism of action and durable efficacy, eltrombopag is often considered a bridging and maintenance treatment option. For most patients with chronic diseases, their thrombocytopenia is likely to persist, so treatment with eltrombopag may continue for months or even years. Interim results of a long-term follow-up study showed that among 299 patients who received eltrombopag for up to 3 years, most patients responded well to the drug, had a high safety profile, and were able to effectively maintain platelet counts within the ideal range. This finding further confirms the value and potential of eltrombopag in the long-term management of thrombocytopenia.